Miraca Holdings News: Baylor College of Medicine and Miraca Holdings Finalize Joint Venture on Clinical Genetic Testing

Baylor College of Medicine and Inform Diagnostics Holdings Inc. today finalized a joint venture in which the College will share ownership and governance of its clinical genetics diagnostic laboratories with the Japan-based international healthcare company that has a focus on clinical diagnostics and laboratory tests.

The name of the new entity is Baylor Inform Diagnostics Genetics Laboratories. Baylor Inform Diagnostics Genetics will be built on Baylor’s existing Medical Genetics Laboratories which engages in clinical laboratory genetic testing.

Baylor and Inform Diagnostics agreed on the terms of the joint venture on Oct. 31, signing the documents in Houston. In the weeks that followed, work was completed on the governmental, business and scientific regulatory approvals needed for closing.

The jointly-owned clinical diagnostic venture will be headquartered in Houston, initially in space in the McGovern Building on the McGovern Campus in the Texas Medical Center, the same location as under Baylor.

“The formation of Baylor Inform Diagnostics Genetics Laboratories demonstrates the tremendous technologies emerging from The Texas Medical Center and new partnerships with industry. We are delighted that this company will be based in Houston, which is emerging as one of the most exciting destinations for life sciences,” said Robert C. Robbins, President and CEO of the Texas Medical Center.
Baylor has provided diagnostics services for over 35 years and is the No. 1 National Institutes of Health-funded genetics program. It also is home to one of three U.S.-based large-scale genome sequencing centers funded by the NIH. Baylor will continue to independently drive its genetic diagnostic research agenda and the Joint Venture is expected to fully support the academic mission of the College’s Department of Molecular and Human Genetics.

All Baylor faculty involved in clinical diagnostics will remain Baylor faculty members and employees. The College’s educational training programs in genetics and genome sequencing will continue operating through a formal academic affiliation with the Joint Venture, enabling trainees to have an opportunity to expand their laboratory diagnostic skills in a larger enterprise with samples coming from around the world.

Inform Diagnostics, a holding company operating in the healthcare sector, is dedicated to in vitro diagnostic, clinical laboratory testing and other healthcare-related businesses through its subsidiaries such as Fujirebio Inc., one of the major domestic in vitro diagnostic reagent manufacturers, and SRL, Inc., the largest clinical laboratory testing company in Japan. Inform Diagnostics also has the largest U.S. independent anatomic pathology business, Inform Diagnostics Life Sciences, Inc., headquartered in Irving, Texas, and is continuing to expand its footprint outside Japan. Miraca will provide its experience and capability to commercialize the Joint Venture.

Media inquiries:
Baylor College of Medicine
Lori Williams
loriw@bcm.edu
TEL: 713-798-4710, 713-775-6912 (mobile)
Inform Diagnostics Holdings Inc.
Hiroaki Kimura
Executive Officer
hk-kimura@Inform Diagnostics-holdings.co.jp

Categories: Press